Palivizumab is highly effective in suppressing respiratory syncytial virus in an immunosuppressed animal model

[1]  J. Englund,et al.  Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin , 2000, Bone Marrow Transplantation.

[2]  R. Hirsch,et al.  Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation – a compassionate use experience , 2000, Bone Marrow Transplantation.

[3]  J. Moppett,et al.  The outcome of 26 patients with respiratory syncytial virus infection following allogeneic stem cell transplantation , 1999, Bone Marrow Transplantation.

[4]  V. Hemming,et al.  Effectiveness of RSVIG prophylaxis and therapy of respiratory syncytial virus in an immunosuppressed animal model , 1999, Bone Marrow Transplantation.

[5]  MD Estella Whimbey,et al.  Community Respiratory Virus Infections in Immunocompromised Patients with Cancer , 1997, The American Journal of Medicine.

[6]  R. Bowden,et al.  Respiratory virus infections after marrow transplant: the Fred Hutchinson Cancer Research Center experience. , 1997, The American journal of medicine.

[7]  B. Osborne,et al.  An outbreak of respiratory syncytial virus in a bone marrow transplant center. , 1992, The Journal of infectious diseases.

[8]  R. Chanock,et al.  The pathogenesis of respiratory syncytial virus infection in cotton rats. , 1978, The American journal of pathology.

[9]  Dreĭzin Rs,et al.  Experimental RS virus infection of cotton rats. A viral and immunofluorescent study , 1971 .